http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yaping Sheng,Qigu Huang,Haibing Huang,Mengshan Yu,Xinli Zhang,Lu Cheng,Zhi Liu,Wei Liu,Jianjun Yi,Wantai Yang 한국공업화학회 2014 Journal of Industrial and Engineering Chemistry Vol.20 No.2
The copolymerization of MMA with ethylene was promoted by metallocene complex in the presence ofinitiator tetra(2,3-epoxy propoxy)silane (Is), reducing agent Zn and cocatalyst MAO, combining freeradical polymerization with coordination polymerization via sequential monomer addition strategy inone-pot to produce 4-arms hydroxy-functionalized PMMA-b-PE. The effects of polymerizationconditions such as temperature, time, ethylene pressure and Al/Ti molar ratio on the polymerizationperformance were investigated. 4-Arms hydroxy-functionalized PMMA-b-PE was obtained by solventextraction and determined by GPC, MALLS, DSC, FT-IR, WAXD and 1H(13C) NMR. The DSC result indicatedthat the 4-arms hydroxy-functionalized PMMA-b-PE had one Tg at 87.0 ℃ and one Tm at 117.0 ℃ whichattributed to Tg of PMMA segment and Tm of PE segment, respectively. The microstructure of 4-armshydroxy-functionalized PMMA-b-PE was further confirmed by WAXD, FT-IR, and 13C NMR analysis. These results demonstrated that the obtained 4-arms block copolymer consisted of PMMA segment andcrystalline PE segment.
The management of hydatidiform mole with lung nodule: a retrospective analysis in 53 patients
Xiao Li,Yaping Xu,Yuanyuan Liu,Xiaodong Cheng,Xinyu Wang,Weiguo Lu,Xing Xie 대한부인종양학회 2019 Journal of Gynecologic Oncology Vol.30 No.2
Objective: To investigate the significance of lung nodule in hydatidiform mole, we retrospectively compared the clinical outcomes of those patients treated with different strategies. Methods: The patients were divided into three groups: chemotherapy immediately once lung nodule was detected (group 1, n=17), delayed chemotherapy until human chorionic gonadotrophin (hCG) level met the diagnostic criteria for gestational trophoblastic neoplasia (GTN) (group 2, n=18), and hCG surveillance alone until hCG level was normalized spontaneously (group 3, n=18). The clinical parameters of these patients were collected and analyzed. Results: Totally 53 (4.0%) patients were included from 1,323 cases with molar pregnancy during past 16 years. Among them, the diameters of lung nodules were 0.3–2.5 cm. Chemotherapy cycles for achieving hCG normalization and the failure rate of first-line chemotherapy in group 1 were significantly increased than that in group 2 (5 vs. 3 cycles, p=0.000, 58.8% vs. 11.1%, p=0.005). The hCG level of all 18 cases in group 3 was normalized spontaneously within 6 months. Of those, lung nodules of 9 patients disappeared spontaneously, accounting for 25% (9/36) of patients who initially selected observation. The proportion of single nodule in group 3 was significantly higher than that in group 2 (10/18 vs. 2/18, p=0.012). Conclusion: Our results suggest that lung nodule alone is not an adequate indication of chemotherapy in molar pregnancy. hCG surveillance is safe for patients with lung nodule, especially with single nodule, as long as their hCG levels do not meet International Federation of Gynecology and Obstetrics diagnostic criteria for GTN.
Ting-Yan Shi,Sheng Yin,Jianqing Zhu,Ping Zhang,Jihong Liu,Libing Xiang,Yaping Zhu,Sufang Wu,Xiaojun Chen,Xipeng Wang,Yin-Cheng Teng,Tao Zhu,Aijun Yu,Yingli Zhang,Yanling Feng,He Huang,Wei Bao,Yanli Li 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.3
Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence. Methods: SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography–computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cycles of platinum-based chemotherapy and niraparib maintenance or 6 cycles of platinum-based chemotherapy and niraparib maintenance alone. Patients who undergo at least 4 cycles of chemotherapy and must be, in the opinion of the investigator, without disease progression, will be assigned niraparib maintenance. Major inclusion criteria are secondary relapsed OC with a platinum-free interval of no less than 6 months and a possibly complete resection. Major exclusion criteria are borderline tumors and non-epithelial ovarian malignancies, received debulking surgery at recurrence and impossible to complete resection. The sample size is 96 patients. Primary endpoint is 12-month non-progression rate. Trial Registration: ClinicalTrials.gov Identifier: NCT03983226